Torsades de Pointes Causes and Risk Factors
Introduction to Torsades de Pointes
- Torsades de pointes (TdP) is most commonly caused by QT-prolonging medications, electrolyte abnormalities, bradycardia, and congenital long QT syndrome, with drug-induced cases accounting for the majority of acquired TdP episodes 1, 2
Medication-Related Causes
- Class IA antiarrhythmic drugs with high risk (1-10% incidence): quinidine, disopyramide, procainamide 1
- Class III antiarrhythmic drugs with high risk (1-10% incidence): sotalol, dofetilide, ibutilide 1
- Other antiarrhythmic drugs: amiodarone (less frequent risk) 1
- Anti-infective agents: clarithromycin, erythromycin, halofantrine, pentamidine, sparfloxacin 1, 2
- Antiemetics: domperidone, droperidol 1
- Antipsychotics: chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide 1
- Opioid dependence agents: methadone 1, 3
- Other medications: arsenic trioxide, bepridil, cisapride 1
Electrolyte Abnormalities
Cardiac Conditions
- Bradycardia (including sinus bradycardia and heart block) 1, 2
- Recent conversion from atrial fibrillation 1
- Congestive heart failure 1
- Left ventricular hypertrophy 1
- Congenital long QT syndrome 1, 4
- Digitalis toxicity 1, 5
Risk Factors and Predisposing Conditions
- Female gender 1, 2
- Advanced age (especially hospitalized elderly patients) 6, 7
- Baseline QT prolongation (QT intervals >500 ms) 1, 6
- Genetic factors: certain DNA polymorphisms even without clinical congenital LQTS 1, 4
- Rapid intravenous drug administration of QT-prolonging medications 1
- High drug concentrations (often due to drug interactions or impaired metabolism) 1
- Combination of multiple QT-prolonging drugs 1, 2
- Combination of QT-prolonging drug with its metabolic inhibitor 1
ECG Features Predicting Torsades de Pointes
- Marked QTc prolongation >500 ms (with exceptions for amiodarone and verapamil) 3, 8
- Prominent U waves and QT-U prolongation, especially after pauses 1, 6
- Short-long-short R-R cycle pattern before TdP onset 3, 6
- T-wave alternans (macroscopic) 3, 8
- Ventricular ectopy and couplets 3, 8
Clinical Pitfalls and Management Considerations
- Drug combinations can significantly increase risk even when individual drugs pose minimal risk 1, 4
- Hospital settings may increase risk due to concurrent illness, electrolyte disorders, and IV drug administration 6, 7
- Immediate management includes discontinuation of offending agent(s) 1, 2
- IV magnesium sulfate 2g (even with normal magnesium levels) 3
- Correction of electrolyte abnormalities (potassium to 4.5-5 mmol/L) 3, 8
- Temporary pacing to increase heart rate if TdP recurs despite other measures 1, 3
- Immediate cardioversion for sustained TdP 3, 8
- Prevention strategies include careful ECG monitoring for QT prolongation in high-risk patients and avoiding combinations of QT-prolonging drugs 3, 6